TCGA-AO-A12D-01A-11R-A115-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 84
- os_event
- false
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1KYGSMA7 | low-grade glioma | — | 0.906 |
| 2 | TCGA-44-7672-01A-11R-2066-07 | — | cohortA1 | 0.893 |
| 3 | MDT-AP-3277 | Med | Medulloblastoma | 0.892 |
| 4 | ERR2278883 | — | — | 0.890 |
| 5 | MBCProject_3554_T2_RNA | — | A | 0.883 |
| 6 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.877 |
| 7 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.875 |
| 8 | TCGA-CN-4733-01A-02R-1873-07 | — | — | 0.873 |
| 9 | TCGA-CR-7394-01A-11R-2016-07 | — | — | 0.872 |
| 10 | MDT-AP-3331 | Med | Medulloblastoma | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |